This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Four Biotech 'Surprise' Stocks for 2014

With Thanksgiving approaching, it's time for investors and commentators to take stock (pun intended) of the rapidly ending year and look ahead with predictions for the next 12 months. 

This week, I want to highlight what were, for me, some of the biggest surprises in the biotech sector of 2013 and speculate about what those same events might look like in 2014. Next week, I'll offer my own biotech stock predictions for 2014 -- a list that will surely come back to haunt me 12 months from now. 

Surprise No. 1 of 2013: The blow-up of approved, marketed drugs due to safety problems. Ariad Pharmaceuticals'  (ARIA) leukemia drug Iclusig pops immediately to mind in this category, but don't forget Affymax's anemia drug Omontys, no less of a disaster from earlier in the year. One doesn't usually plan for commercial-stage biotech companies completely blowing up, but that's exactly what happened to Ariad and Affymax to the surprise of most investors. The risk of a drug failure is something we more often associate with clinical trials, not drugs that make their way successfully through clinical trials and the FDA approval process. Yet in 2013, Ariad and Affymax managed to snatch failure from the jaws of victory. 

Is there an Ariad/Affymax lurking in 2014? I don't believe there is, but press me and I'll say Seattle Genetics  (SGEN) and its lymphoma drug Adcetris. I own Seattle Genetics so I'm not here to instill panic. Nonetheless, the bear thesis on Adcetris does focus, in part, on the drug's safety. An Adcetris study was halted temporarily in June due to reports of pancreatitis and the drug has been linked to cases of progressive multifocal leukoencephalopathy (PML). Again, I believe the risk of Seattle Genetics falling into the same deep, dark hole as Ariad and Affymax is exceedingly small -- under 1% -- but as we learned this year, nothing is impossible. 

Surprise No. 2 of 2013: The acquisition of a late stage/commercial antibiotic company. Cubist Pharmaceuticals  (CBST) acquired Trius Therapeutics and Optimer Pharmaceuticals in July. I've long been bullish on smaller antibiotic companies because of the growing problem of drug-resistant germs and the relative scarcity of new, effective antibiotics. Up until this year, however, owning small antibiotic makers has been a lonely experience because larger drug companies have been exiting the antibiotic market, shrinking the pool of natural buyers. But Roche has signaled a move back into antibiotic development, so we may see more M&A activity in 2014. 

Is there a Trius or Optimer in 2014? Yes, and it's Cempra (CEMP). Granted, Cempra won't have results from a phase III study of its antibiotic solithromycin until the middle of 2014, where Trius had completed late-stage studies already when it was acquired, but if there is going to be more antibiotic M&A, Cempra is a target. 

Surprise No. 3 in 2013: A better-than-expected commercial launch of a new drug. I'm going to cheat a little on this one and choose Regeneron Pharmaceuticals'  (REGN) Eylea, which was approved in 2011 and launched in 2012. What's amazing about Eylea -- and why a mention is deserved here -- is investors continued to under-estimate the drug's sales potential throughout 2013. The Eylea upside has contributed a lot to Regeneron's incredible stock performance. 

Can a new drug launch in 2014 knock the socks off investors like Eylea has done the past two years? I have two contenders: Pharmacyclics'  (PCYC) Imbruvica and Gilead Sciences'  (GILD) sofosbuvir. Investors have high expectations for both drugs already but they're also game-changing therapies launching into large commercial markets. I won't be surprised to see Imbruvica, sofosbuvir, or both, end 2014 with sales topping current expectations.

Sobek is long Seattle Genetics, Cubist, Pharmacyclics, and Cempra.

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs